Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
A large number of patients are switched to second-line antiretroviral therapy, especially in resource limited settings. Lopinavir/Ritonavir is the main drug used in second-line treatment regimens. We describe a patient attending an HIV treatment centre in Kampala, Uganda, who presented with bilateral non-tender pitting inflammatory edema two weeks after switching to a Lopinavir/Ritonavir-containing second-line treatment regimen. The lack of an alternate explanation led us to suspect that Lopinavir/Ritonavir was potentially responsible for the edema.
Shihab
Hasan M
HM
Infectious Diseases Institute, Makerere University, Kampala, Uganda. hshihab@jhsph.edu
Lutwama
Fred
F
Piloya
Theresa
T
Castelnuovo
Barbara
B
Kambugu
Andrew D
AD
Colebunders
Robert
R
D019380:Anti-HIV Agents / Q000009:adverse effects*; D004487:Edema / Q000473:pathology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007866:Leg / Q000473:pathology*; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects*; D014454:Uganda
D019380:Anti-HIV Agents; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir